Last viewed: VCYT

Prices are updated after-hours

VCYT

Veracyte, Inc.

VCYT | $19.23 1.96% 1.92% 810K

|

Health Technology

(0.0% 1d) (-11.2% 1m) (-15.5% 1y) (0.0% 2d) (1.8% 3d) (-0.9% 7d) (24.0% volume)
Earnings Calendar: 2024-02-22
Market Cap: $ 1,443,554,236
http://www.veracyte.com
Sec Filling | Patents | 354 employees

(US) Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.

cancer lung cancer fibrosis lungs diagnostics

add to watch list Paper trade email alert is off

Press-releases

Veracyte Announces that Nine Studies Reinforcing the Value of Decipher Prostate and Decipher Bladder Testing Will Be Presented at AUA 2024
Published: 2024-04-16 (Crawled : 14:00) - biospace.com/
VCYT | $19.23 1.96% 1.92% 810K

|

Health Technology

| -0.88% | O: -0.93% H: 0.0% C: -1.41%
bladder

Veracyte’s Decipher Prostate Test Receives Highest Evidence-Level Rating Among Molecular Tests in Updated Prostate Cancer NCCN Guidelines
Published: 2024-02-27 (Crawled : 00:00) - biospace.com/
VCYT | $19.23 1.96% 1.92% 810K

|

Health Technology

| -18.51% | O: 0.68% H: 0.34% C: -0.42%
guidelines test cancer molecular

Veracyte to Participate in the Raymond James 45th Annual Institutional Investors Conference
Published: 2024-02-21 (Crawled : 00:00) - biospace.com/
VCYT | $19.23 1.96% 1.92% 810K

|

Health Technology

| -23.29% | O: -0.8% H: 0.93% C: -1.17%
conference

Veracyte to Release Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024
Published: 2024-02-08 (Crawled : 00:00) - biospace.com/
VCYT | $19.23 1.96% 1.92% 810K

|

Health Technology

| -21.18% | O: 0.33% H: 2.82% C: 2.29%
financial results

Veracyte Completes Acquisition of C2i Genomics
Published: 2024-02-06 (Crawled : 14:00) - biospace.com/
VCYT | $19.23 1.96% 1.92% 810K

|

Health Technology

| -21.7% | O: 0.45% H: 7.5% C: 3.33%
genomics acquisition

World Molecular Diagnostics Market Research Report 2023-2028 - Companion Diagnostics and Molecular Pharmacokinetics Revolutionizes Drug Therapies
Published: 2024-01-19 (Crawled : 01:00) - prnewswire.com
TMO | News | $541.52 -1.05% 0.61% 2.1M

|

Health Technology

| -0.76% | O: 1.46% H: 0.0% C: 0.0%
BIO | News | $281.02 -3.38% -0.36% 370K

|

Health Technology

| -10.3% | O: 0.14% H: 1.0% C: 0.68%
VCYT | $19.23 1.96% 1.92% 810K

|

Health Technology

| -24.85% | O: 0.12% H: 0.35% C: -0.2%
NSTG | $0.1053 -37.43% -0.19% 0

|

Health Technology

| -74.19% | O: -1.96% H: 0.0% C: 0.0%
MYGN F | $18.51 -0.7% -0.7% 640K

|

Health Technology

| -7.72% | O: 1.04% H: 0.49% C: -0.49%
ILMN | $116.64 -1.4% -1.41% 1.8M

|

Health Technology

| -11.88% | O: -0.18% H: 2.05% C: 1.4%
HOLX | $75.1 0.24% 0.24% 1.6M

|

Health Technology

| 1.86% | O: 0.29% H: 0.07% C: -0.33%
CDNA | $8.08 -2.42% -2.48% 670K

|

Health Technology

| -18.65% | O: 0.62% H: 0.51% C: -4.74%
drug report world research companion diagnostics molecular market

Veracyte Announces Preliminary Full-Year 2023 Results, Acquisition of C2i Genomics to Add Minimal Residual Disease Capabilities to Its Novel Diagnostics Platform
Published: 2024-01-08 (Crawled : 18:00) - biospace.com/
MS | News | $90.26 0.2% 0.0% 6.7M

|

| -2.75% | O: -0.03% H: 0.67% C: 0.32%
VCYT | $19.23 1.96% 1.92% 810K

|

Health Technology

| -25.38% | O: 2.53% H: 10.54% C: 10.31%
disease genomics acquisition diagnostics platform

Real-World Data Presented at SUO 2023 Show that Veracyte’s Decipher Genomic Classifier Identifies Patients Whose Prostate Cancer is Likely to Progress
Published: 2023-12-01 (Crawled : 23:00) - biospace.com/
VCYT | $19.23 1.96% 1.92% 810K

|

Health Technology

| -25.0% | O: -0.51% H: 4.28% C: 4.2%
genomic cancer show

Clinical Validation Data Published in CHEST Demonstrate that Veracyte’s Percepta Nasal Swab Test Improves Lung Cancer Risk Assessment for Patients with Lung Nodules
Published: 2023-11-29 (Crawled : 15:00) - biospace.com/
VCYT | $19.23 1.96% 1.92% 810K

|

Health Technology

| -25.52% | O: 1.9% H: 2.74% C: -2.06%
lung test cancer risk

Cancer Biopsy Market Share is Expected to Reach USD 92.09 Billion By 2032, Growing at 14.8% CAGR: Polaris Market Research
Published: 2023-11-27 (Crawled : 15:30) - prnewswire.com
TMO | News | $541.52 -1.05% 0.61% 2.1M

|

Health Technology

| 9.06% | O: 0.1% H: 0.86% C: 0.19%
QGEN | $39.47 0.61% 0.0% 950K

|

Health Technology

| -4.16% | O: 0.37% H: 0.46% C: -1.1%
PHG | $19.98 -0.84% 0.0% 500K

|

Health Technology

| -5.62% | O: 0.09% H: 0.7% C: 0.47%
DHR | $236.36 -1.27% 0.0% 4.2M

|

Health Technology

| 8.55% | O: -0.41% H: 0.67% C: -0.23%
BIO | News | $281.02 -3.38% -0.36% 370K

|

Health Technology

| -12.34% | O: -0.71% H: 0.05% C: -0.6%
BDX | $233.15 0.41% 0.15% 890K

|

Health Technology

| -3.3% | O: -0.1% H: 0.73% C: 0.08%
ABT | News | $105.27 -0.6% -0.15% 7.3M

|

Health Technology

| 3.5% | O: -0.2% H: 0.85% C: 0.11%
VCYT | $19.23 1.96% 1.92% 810K

|

Health Technology

| -26.69% | O: -0.95% H: 2.93% C: 1.66%
QGEN | $39.47 0.61% 0.0% 950K

|

Health Technology

| -4.16% | O: 0.37% H: 0.46% C: -1.1%
NEO | News | $13.79 0.8% 0.8% 910K

|

Health Services

| -28.92% | O: -0.16% H: 0.21% C: -1.14%
MYGN F | $18.51 -0.7% -0.7% 640K

|

Health Technology

| 3.44% | O: -0.55% H: 1.45% C: 0.5%
ILMN | $116.64 -1.4% -1.41% 1.8M

|

Health Technology

| 20.29% | O: -1.5% H: 0.97% C: -2.28%
HOLX | $75.1 0.24% 0.24% 1.6M

|

Health Technology

| 4.43% | O: -0.42% H: 0.43% C: 0.13%
expected reach cancer research growing market

See all

Last 15 days Sec forms

File Id	Form	Published Date	Transaction Date	Direction	Code	Amount Transacted	Owned Amount
0001384101-24-000028	4	2024-03-05	2024-03-02	Sell	F	2337	25116
0001384101-24-000027	4	2024-03-05	2024-03-01	Sell	M	10000	0
0001384101-24-000027	4	2024-03-05	2024-03-01	Sell	S	10000	37601
0001384101-24-000027	4	2024-03-05	2024-03-01	Buy	M	10000	47601
0001384101-24-000026	4	2024-03-05	2024-03-02	Sell	F	6112	84717
0001384101-24-000025	4	2024-03-05	2024-03-02	Sell	F	3008	35679

Your Today's Watch List

Sign in to create a watchlist

Gainers vs Losers

64%

36%

Top 10 Gainers

AGBA | News | $1.02 155.0% 57.94% 120M

|

ZCMD | $2.86 108.76% 52.1% 2.3M

|

Commercial Services

INVO | $1.555 104.6% 51.13% 5M

|

Health Technology

ISPC | $0.437 105.16% 49.53% 37M

|

Professional, Scientific, and T...

WLGS | News | $0.92 84.0% 45.65% 1.6M

|

OST | $0.499 21.38% 45.26% 1.9M

|

XPON | News | $3.1 60.62% 37.74% 17M

|

TIRX | $0.7 44.39% 30.74% 58M

|

BNTC | News | $6.92 44.17% 30.64% 3.5M

|

Health Technology

GGE | $0.035 19.86% 29.3% 64M

|

Last 48 Hours Insiders Buying

AXR P 2400 | $22.17 2.69% 0.0% 5.5K

|

| 21:00
QCRH P 118 | $55.405 1.33% 1.31% 54K

|

| 18:01
VUZI P 7500 | $1.26 3.28% 3.17% 1M

|

Electronic Technology

| 18:00
RMCF | $3.61 2.27% 2.22% 18K

|

Consumer Non-Durables

| 20:10

12 months watchlist earnings calendar